Bulletin
Investor Alert

New York Markets After Hours

Market Snapshot Winners and Losers

Dynavax Technologies Corp.

NAS: DVAX

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Dynavax Technologies Corp.

After Hours

 --Quotes are delayed by 20 min

May 27, 2022, 4:44 p.m.

DVAX
/zigman2/quotes/203017054/composite

$

12.42

Change

-0.0100 -0.08%

Volume

Volume 59,235

Quotes are delayed by 20 min

/zigman2/quotes/203017054/composite

Today's close

$ 11.68

$ 12.43

Change

+0.75 +6.42%

Day low

Day high

$11.57

$12.46

Open

52 week low

52 week high

$7.26

$21.39

Open

Company Description

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in ad...

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Valuation

P/E Current

21.53

P/E Ratio (with extraordinary items)

16.67

P/E Ratio (without extraordinary items)

25.94

Price to Sales Ratio

4.28

Price to Book Ratio

7.78

Price to Cash Flow Ratio

5.52

Enterprise Value to EBITDA

8.48

Enterprise Value to Sales

2.54

Efficiency

Total Asset Turnover

0.63

Liquidity

Current Ratio

1.75

Quick Ratio

1.64

Cash Ratio

0.98

Profitability

Gross Margin

60.28

Operating Margin

30.43

Pretax Margin

17.74

Net Margin

16.51

Return on Assets

10.36

Return on Equity

51.34

Return on Total Capital

35.17

Capital Structure

Total Debt to Total Assets

24.77

Officers and Executives

Name Age Officer Since Title
Mr. Scott D. Myers 55 2021 Chairman
Mr. David F. Novack 58 2013 Co- President & Senior Vice President-Operations
Mr. Ryan Spencer 42 2005 Senior Vice President-Commercial
Ms. Kelly MacDonald 36 2021 Chief Financial Officer & Senior Vice President
Dr. Patricia Novy - 2021 ice President-Medical Affairs

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/17/2022 Justin Burgess
Principal Accounting Officer 		6,000   Disposition at $10 per share. 60,000
05/16/2022 Justin Burgess
Principal Accounting Officer 		6,000   Derivative/Non-derivative trans. at $0 per share. 0
03/03/2022 Ryan Spencer
CEO and Director; Director 		52,835   Disposition at $10.56 per share. 557,937
03/03/2022 Ryan Spencer
CEO and Director; Director 		17,611   Disposition at $10.57 per share. 186,148
03/03/2022 Ryan Spencer
CEO and Director; Director 		12,662   Disposition at $10.57 per share. 133,837
03/03/2022 David F. Novack
President & COO 		31,079   Disposition at $10.57 per share. 328,505
03/03/2022 David F. Novack
President & COO 		10,783   Disposition at $10.57 per share. 113,976
03/03/2022 Robert Janssen
Senior Vice President 		17,760   Disposition at $10.57 per share. 187,723
03/03/2022 Robert Janssen
Senior Vice President 		6,276   Disposition at $10.56 per share. 66,274
03/03/2022 Justin Burgess
Principal Accounting Officer 		6,000   Disposition at $10.58 per share. 63,480
03/03/2022 Justin Burgess
Principal Accounting Officer 		3,167   Disposition at $10.58 per share. 33,506
03/03/2022 Justin Burgess
Principal Accounting Officer 		8,417   Disposition at $10.58 per share. 89,051
03/03/2022 Justin Burgess
Principal Accounting Officer 		3,906   Disposition at $10.58 per share. 41,325
03/02/2022 Ryan Spencer
CEO and Director; Director 		29,750   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2022 Ryan Spencer
CEO and Director; Director 		20,833   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2022 David F. Novack
President & COO 		17,500   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2022 Robert Janssen
Senior Vice President 		10,000   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2022 Justin Burgess
Principal Accounting Officer 		6,000   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2022 Justin Burgess
Principal Accounting Officer 		3,167   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2022 Justin Burgess
Principal Accounting Officer 		8,417   Derivative/Non-derivative trans. at $0 per share. 0
03/02/2022 Justin Burgess
Principal Accounting Officer 		3,906   Derivative/Non-derivative trans. at $0 per share. 0
02/15/2022 Ryan Spencer
CEO and Director; Director 		1,457   Award at $10.29 per share. 14,992
02/15/2022 David F. Novack
President & COO 		1,009   Award at $10.29 per share. 10,382
02/15/2022 Robert Janssen
Senior Vice President 		467   Award at $10.29 per share. 4,805
02/15/2022 Justin Burgess
Principal Accounting Officer 		133   Award at $10.29 per share. 1,368
02/10/2022 Ryan Spencer
CEO and Director; Director 		89,250   Derivative/Non-derivative trans. at $0 per share. 0
02/10/2022 David F. Novack
President & COO 		52,500   Derivative/Non-derivative trans. at $0 per share. 0
02/10/2022 Robert Janssen
Senior Vice President 		30,000   Derivative/Non-derivative trans. at $0 per share. 0
11/17/2021 Robert Janssen
Senior Vice President 		53,431   Disposition at $17.07 per share. 912,067
11/17/2021 Robert Janssen
Senior Vice President 		53,431   Derivative/Non-derivative trans. at $10.47 per share. 559,422
11/16/2021 Robert Janssen
Senior Vice President 		35,974   Disposition at $17.16 per share. 617,313
11/16/2021 Robert Janssen
Senior Vice President 		35,974   Derivative/Non-derivative trans. at $10.47 per share. 376,647
11/01/2021 David F. Novack
President & COO 		20,000   Disposition at $20.12 per share. 402,400
10/07/2021 David F. Novack
President & COO 		3,000   Disposition at $18 per share. 54,000
/news/latest/company/us/dvax

MarketWatch News on DVAX

  1. Valneva Stock Is Jumping on European Vaccine Supply Deal

    9:52 a.m. Nov. 24, 2021

    - Barron's Online

  4. The U.K. Canceled a Vaccine Deal. Here's the Fallout for Stocks.

    9:33 a.m. Sept. 13, 2021

    - Barron's Online

  10. Dynavax, Mount Sinai to work on universal flu vaccine

    10:02 a.m. July 16, 2020

    - Jaimy Lee

  11. Get ready for the stock market bubble to burst

    1:50 p.m. July 11, 2020

    - Cody Willard

  13. Dynavax started at outperform with $14 stock price target at Evercore ISI

    6:22 a.m. June 15, 2020

    - Tomi Kilgore

  15. Dynavax's stock rises 10% on expanded CEPI partnership

    11:56 a.m. March 26, 2020

    - Jaimy Lee

  16. Dynavax, Fastly, PulteGroup, and Other 13D Filings

    9:30 p.m. Aug. 30, 2019

    - Barron's Online

  17. A Biotech Pro Loaded Up on These 2 Stocks

    7:30 a.m. June 23, 2019

    - Barron's Online

  18. Dynavax announces layoffs, CEO retirement

    5:25 p.m. May 23, 2019

    - Claudia Assis

  19. Dynavax Technologies upgraded to overweight from neutral at J.P. Morgan

    7:52 a.m. May 10, 2018

    - Tomi Kilgore

  20. Dynavax shares rise 14% on promising cancer conference data

    9:10 a.m. April 16, 2018

    - Emma Court

  21. Loading more headlines...
/news/nonmarketwatch/company/us/dvax

Other News on DVAX

  1. Dynavax: Evolving Endemic Situation Adds To Its Risk

    11:59 a.m. May 23, 2022

    - Seeking Alpha

  3. Why Dynavax Stock Blasted 16% Higher Today

    6:01 p.m. May 19, 2022

    - Motley Fool

  4. Why Dynavax Stock Won on a Losing Monday for the Market

    6:46 p.m. May 16, 2022

    - Motley Fool

  6. RIOT, MARA and DM among pre market gainers

    8:32 a.m. May 13, 2022

    - Seeking Alpha

  7. Is Novavax Stock A Buy, Sell, Or Hold After Recent Earnings?

    2:12 p.m. May 11, 2022

    - Seeking Alpha

  12. 10-Q: DYNAVAX TECHNOLOGIES CORP

    4:24 p.m. May 5, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  15. Why Dynavax Stock Was Winning This Week

    9:20 a.m. March 18, 2022

    - Motley Fool

  17. Dynavax Technologies (DVAX) Investor presentation - Slideshow

    10:52 a.m. March 12, 2022

    - Seeking Alpha

  18. Biotech 101 Lecture 3: Looking At Major Biotech Catalysts

    3:23 p.m. March 8, 2022

    - Seeking Alpha

  19. The Alphavaxers: Dynavax And Novavax - A Tale Of Two Cities

    4:28 a.m. March 7, 2022

    - Seeking Alpha

  20. ChemoCentryx (CCXI) Q4 Earnings and Sales Miss Estimates

    10:33 a.m. March 2, 2022

    - Zacks.com

  21. Loading more headlines...

At a Glance

Dynavax Technologies Corp.

2100 Powell Street

Suite 900

Emeryville, California 94608

Phone

1 5108485100

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

View SEC Filings

Revenue

$437.04M

Net Income

$72.14M

Employees

311.00

Annual Report for DVAX

/news/pressrelease/company/us/dvax

Press Releases on DVAX

  7. Dynavax Reports First Quarter 2022 Financial Results

    4:02 p.m. May 5, 2022

    - PR Newswire - PRF

  12. Global Antibiotic Resistance Market to Hit US$16.5 Billion By 2030

    8:51 a.m. April 21, 2022

    - Financial News Media

  13. Global Antibiotic Resistance Market to Hit US$16.5 Billion By 2030

    8:50 a.m. April 21, 2022

    - PR Newswire - PRF

  19. Clover To Present at World Vaccine Congress Washington 2022

    6:30 a.m. April 12, 2022

    - GlobeNewswire

  21. Loading more headlines...
Link to MarketWatch's Slice.